Briacell Therap (BCTX) to Release Quarterly Earnings on Monday

Briacell Therap (NASDAQ:BCTX) is projected to post its results before the market opens on Monday, December 15th. Analysts expect Briacell Therap to post earnings of ($12.11) per share for the quarter.

Briacell Therap Trading Down 6.9%

NASDAQ:BCTX opened at $11.39 on Monday. The firm has a market cap of $21.41 million, a PE ratio of -0.14 and a beta of 1.39. The stock has a fifty day moving average price of $11.05 and a 200 day moving average price of $15.26. Briacell Therap has a 12-month low of $6.00 and a 12-month high of $190.50.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Briacell Therap stock. Citadel Advisors LLC bought a new stake in Briacell Therap (NASDAQ:BCTX) during the third quarter, according to its most recent disclosure with the SEC. The firm bought 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned about 1.63% of Briacell Therap at the end of the most recent reporting period. Institutional investors and hedge funds own 15.42% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Briacell Therap in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $320.00.

Briacell Therap Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.